Over the projected period, an increasing number of product launches related to anti-microbial medicines is anticipated to fuel the growth of the worldwide cell expansion market. For instance, in October 2022, Merck, a pioneer in research and technology around the world, introduced a new VirusExpress Lentiviral Production Platform based on its expertise as a company that performs contract research, development, and manufacture. By overcoming production barriers for lentiviral vectors, this novel platform can reduce process development time by about 40%. By streamlining the upstream procedure, Merck's VirusExpress Platform makes cell and gene therapy development simpler to control, modify, and scale.
The global cell expansion market is anticipated to increase over the duration of the projected period as a result of market participants increasing their investments in biotechnology goods linked to cell and gene therapy. For instant, February 2022, the life sciences strategic investment fund has been launched by the global corporation FUJIFILM Corporation, based in Japan. It will be managed by the Life Sciences Corporate Venture Capital (LS-CVC), a recently formed entity under Fujifilm's Life Sciences Strategy Headquarters in Tokyo. Fujifilm will invest US$54 million internationally, with an emphasis on cutting-edge biotechnology through collaborations with startup businesses. The company's existing life science investment portfolio, which comprised investments in regenerative medicine, cell treatments, and drug development research goods, will also be managed by the LS-CVC in addition to managing this new fund.
The development of specialised stem cell manufacturing and expansion facilities is anticipated to fuel the worldwide cell expansion market over the course of the forecast period. For instance, April 2022, Cellistic, an iPSC cell therapy CDMO, was introduced by Ncardia, a pioneer in contract research, development, and manufacture of induced pluripotent stem cell (iPSC)-based solutions (Contract Development and Manufacturing Organization). The creation and manufacture of human iPSC-based cell therapies is the primary focus of Cellistic. Innovative cell therapy developers wanting to market cutting-edge therapeutics will find Celletic to be an excellent partner because to its knowledge and focus on iPSC reprogramming, differentiation, and expansion protocols. However, the ethical issues surrounding the use of cell expansion to develop new research results and clinical experimentation are a particular hindrance to the advancement of the market. Other constraints on the growth of the cell expansion market include the need for a skilled workforce and high-tech instrumentation.
Due to an increase in product launches in the region, North America is anticipated to have a leading position in the global cell expansion market over the forecast period. For instance, in July 2020, the Corning X-SERIES cell processing platform has been introduced, according to Corning Incorporated, a global technological business with headquarters in the United States. Using the platform, human blood and blood products can be processed quickly, sterilely, automatically, and efficiently to produce pure immune cell populations for cell and gene therapy applications.
Cell expansion market are expected to generate the biggest revenue share in North America during the forecasted period. The substantial market share of this industry is primarily explained by the increasing cancer incidence, increasing government funding, increasing stem cell therapy research activities, growing public awareness of cutting-edge treatment options, increasing geriatric population, and the substantial presence of industry players in the region. Moreover, in the upcoming years, the region will continue to hold the top spot because to increasing government funding initiatives that have sped up the production of stem cells and the development of regenerative medicine and cellular therapy products. This in turn increases the demand for cell expansion platforms in this region. For instance, The FDA and the Medical Technology Enterprise Consortium (MTEC) provided USD 5.3 million in funding to the Southwest Research Institute (SwRI) in October 2019. (US). These funds were employed by the SwRI to propagate cells for the development of customised regenerative medicine. The ability of the area to produce income is improved by these investments.
The Asia Pacific cell expansion market is anticipated to experience fastest revenue growth throughout the forecast period. Due to increased efforts made by numerous local pharmaceutical and biotechnology companies to develop and market their cellular therapies. Additionally, Asia Pacific will expand at the rapid speed throughout the projection period and offer attractive opportunities for major participants in the cell expansion technologies market due to its quick economic development and low operating costs.
Some of the prominent players in the global cell expansion market include, Beckman Coulter, Inc, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Terumo BCT, Inc., Takara Bio, Inc., Corning, Inc., Stemcell Technologies, Inc., GE Healthcare, Merck KGaA (Sigma-Aldrich Co. LLC), Lonza, Miltenyi Biotec, Octane Biotech, Inc., Corning Incorporated, Eppendorf AG, and Lonza Group.